Nektar Therapeutics holds 2026 annual meeting; all four proposals approved

NEKTAR THERAPEUTICS

Howard W. Robin elected director with 13,164,879 for, 4,975,288 against, 286,175 abstain; broker non-votes 4,588,835.
Equity plan amendment to increase authorized shares by 3,000,000 approved: 13,160,661 for, 4,902,925 against, 362,756 abstain.
Ratification of Ernst & Young as auditor for FY 2026 approved: 22,591,556 for, 118,592 against, 305,029 abstain.
Advisory say-on-pay resolution approved: 18,154,226 for, 161,005 against, 111,111 abstain; broker non-votes 4,588,835.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

NEKTAR THERAPEUTICS shareholders approved Election of Director Howard W. Robin at the 2026-06-04 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The individual listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the “Board”) until the Company’s 2029 Annual Meeting of Stockholders.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

NEKTAR THERAPEUTICS shareholders approved Approve amendment to the Amended and Restated 2017 Performance Incentive Plan to increase authorized shares by 3,000,000 shares at the 2026-06-04 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares was approved with the following votes.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

NEKTAR THERAPEUTICS shareholders approved Ratify selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved with the following votes.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

NEKTAR THERAPEUTICS shareholders approved Approve non-binding advisory resolution regarding executive compensation at the 2026-06-04 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-04

Exact text from the filing

The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.

View on SEC.gov

995 shareholder votes filed in the last 30 days. Browse all shareholder votes →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-26-065845

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.